Tardive Dyskinesia Market Projected to Hit 8.1% Annual Growth by 2036

The United States remains the dominant force in the treatment landscape, accounting for approximately 98% of the total market size within the seven major markets surveyed. This concentration is largely attributed to the widespread use of antipsychotic medications for conditions such as schizophrenia and bipolar disorder, which increases the patient pool at risk for developing the movement disorder. While current standards of care rely heavily on VMAT2 inhibitors like valbenazine and deutetrabenazine, these treatments primarily manage symptoms rather than reversing underlying neurobiological dysfunction.

Future market dynamics are expected to shift as a new generation of drugs moves through clinical pipelines. Assets such as Neurocrine Biosciences' NBI-1065890, SOM Biotech's SOM3355, and Luye Pharma's LY03015 aim to provide improved selectivity and tolerability. Aparna Thakur, a project manager at DelveInsight, notes that these next-generation treatments offer potential improvements in patient adherence by addressing the limitations of existing options, such as somnolence and cardiovascular risks. As these candidates mature, they are expected to broaden the therapeutic toolkit beyond the current reliance on dopamine-depleting agents.